Patient tailored medicines: The impact of race and genetics on medicine

One of the more controversial elements of advancing technology is the use of race and genetics to help create more specific types of medicines that will help combat diseases and conditions that appear to be more prevalent within certain races or ethnic groups than in others. Considering the history of discrimination and inadequate treatment of individuals on the bases of race and gender in the United States, there is justifiable concern that race or gender-based treatment could be used to legitimate discrimination. On the other hand, there is substantial proof that the current method of creating medicines for the general public is problematic and could prevent effective treatments from reaching the marketplace. This presentation addresses the relevance of genetic information, and how race and genetics have affected and may impact the development of medicines, pharmacogenomics, and personalized medicine in the Untied States. This presentation also examines current and proposed federal and state laws and regulations intended to protect individuals from the misuse of genetic information, including the uses that discriminate based on genetic predispositions. We will also explore the potential for litigation and defenses against both manufactures and providers, as well as legal issues relating to research that relies on the use of genetic information.